china is host to 70 percent of all car cell therapy trials registered in 2017 and the first four months of 2018 (150 out of 214).
.
.
suven life sciences' pashamylaram facility successfully completes usfda inspection
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
. severe psoriasis. credit: penn medicine
.
.
.